Jazz Pharmaceuticals plc 2012 Executive Officer Compensation Arrangements
This document outlines the 2012 compensation arrangements for executive officers of Jazz Pharmaceuticals plc. It specifies the annual base salary rates and target bonus percentages for each executive, including the CEO, CFO, and other key officers. The agreement details when certain executives assumed their roles and the effective dates for salary rates. The primary purpose is to formalize the compensation structure for the company's top management for the year 2012.
Exhibit 10.3
2012 Executive Officer Compensation Arrangements
| Executive Officer | Base Salary Rate(1) | Target Bonus as % of Annual Base Salary Rate | ||||
| Bruce C. Cozadd Chairman and Chief Executive Officer | $ | 750,000 | 100 | |||
| Kathryn E. Falberg Executive Vice President and Chief Financial Officer | $ | 460,000 | 50 | |||
| Russell J. Cox Executive Vice President and Chief Commercial Officer | $ | 390,000 | 50 | |||
| Suzanne Sawochka Hooper(2) Executive Vice President and General Counsel | $ | 465,000 | 50 | |||
| Fintan Keegan(3) Executive Vice President, Technical Operations | € | 265,000 | 50 | |||
| Jeffrey K. Tobias, M.D. Executive Vice President, Research and Development and Chief Medical Officer | $ | 425,000 | 50 | |||
| Karen J. Wilson Vice President, Finance and Principal Accounting Officer | $ | 266,500 | 20-35 | |||
| (1) | Base salary rate beginning on March 1, 2012. |
| (2) | Ms. Hooper assumed her position effective on March 12, 2012. |
| (3) | Mr. Keegan assumed his position effective on August 1, 2012. |
